Patritumab deruxtecan is a specifically engineered HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and Merck .

Based on these overall survival data, Merck previously withdrew its biologics license application seeking FDA approval of patritumab deruxtecan for use in this setting. Additional Efficacy Data ...

Merck, Daiichi Sankyo Say Biologics License Application Withdrawn For Patritumab Deruxtecan May 29, 2025 — 08:06 am EDT Written by RTTNews.com for RTTNews -> ...